Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

Year to date, shares of Ironwood have risen 26.4% against the industry’s decline of 3.7%.

Image Source: Zacks Investment Research

IRWD's Q2 Earnings in Details

As reported by its partner AbbVie ABBV, Ironwood’s sole marketed product, Linzess (linaclotide), generated net sales of $282.3 million in the United States, up 14% year over year. Linzess sales were boosted by higher demand and better pricing, helped by the removal of inflation-related rebates and the favorable timing of rebate adjustments.

Total prescription demand for Linzess increased 4% year over year during the second quarter.

IRWD and ABBV share Linzess’ brand collaboration profits and losses equally.

Ironwood’s share of net profit from sales of Linzess in the United States (included in collaborative revenues) totaled $110 million, reflecting a 28% year-over-year increase.

Ironwood also has agreements with two partners, Astellas Pharma and AstraZeneca AZN, related to the development and commercialization of Linzess in Japan and China, respectively.

Astellas and AstraZeneca have exclusive rights to develop and market the drug in their respective territories. Both companies are liable to pay royalties to Ironwood on net Linzess revenues earned in their regions.

Ironwood's royalties and other revenues were $3 million in the second quarter of 2026. In the year-ago quarter, the company recorded royalties and other revenues of negative $0.5 million.

Total cost and expenses (including research and development expenses, selling, general and administrative expenses and restructuring expenses) in the second quarter were $33.7 million, down 15.5% from the year-ago quarter.

Ironwood recorded adjusted EBITDA of $83 million in the reported quarter, up 65.7% year over year.

As of June 30, 2026, Ironwood had cash and cash equivalents worth $79.1 million compared with $220.5 million as of March 31, 2026.

IRWD's 2026 Guidance

Ironwood raised its full-year 2026 revenue guidance, reflecting higher demand for Linzess.

The company now expects total revenues to be in the range of $460 to $485 million in 2026 compared with the previous expectation of $450 to $475 million.

U.S. sales of Linzess (to be recorded by AbbVie) are now expected to be in the range of $1.15-$1.20 billion versus the earlier projection of $1.13-$1.18 billion in 2026.

Ironwood now expects to deliver an adjusted EBITDA of more than $310 million in 2026, indicating effective cost management. Previously, the company expected to deliver an adjusted EBITDA of more than $300 million.

IRWD's Recent Key Updates

In May 2026, the FDA approved the expanded use of Linzess for the treatment of functional constipation (FC) in pediatric patients aged two years and older. The therapy was previously approved for FC in children and adolescents aged six to 17 years. Linzess is the only FDA-approved daily treatment for pediatric FC.

Linzess is already approved for the treatment of irritable bowel syndrome with constipation in adults and pediatric patients aged seven years and above. The drug is also approved for chronic idiopathic constipation in adults.

Ironwood is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (“PS”).

The confirmatory phase III STARS-2 study evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) is now actively recruiting patients. The primary endpoint of the STARS-2 study will check the relative change from baseline in actual weekly PS volume at week 24 in the given patient population.

Ironwood acquired the rights to develop and commercialize apraglutide following the acquisition of VectivBio in June 2023.

IRWD’s Zacks Rank & Stock to Consider

Ironwood currently carries a Zacks Rank #3 (Hold).

A better-ranked stock in the biotech sector is Liquidia Corporation LQDA, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 159.3% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research